Overview
DOTTIKON EXCLUSIVE SYNTHESIS AG manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical, biotech, and pharmaceutical industry.
The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 110 years guides the innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development, clear and transparent data, and process documentation and close customer communication.
History
DOTTIKON EXCLUSIVE SYNTHESIS AG's roots date back to 1913, when the company was founded under the name of Schweizerische Sprengstoff-Fabrik AG (SSF), a specialist in explosives.
From the 1930s to the 1970s, SSF developed processes for nitration, hydrogenation and oxidation, which evolved into the chemical intermediates business and the production based hazardous chemical reactions that the company still excels in today. In 1987, the today named EMS-CHEMIE HOLDING AG purchased the company and officially changed its name to Ems-Dottikon AG end of 1989. Amid a spin-off from EMS-CHEMIE HOLDING AG in 2005, the company received its current name, DOTTIKON EXCLUSIVE SYNTHESIS AG, and the parent company DOTTIKON ES HOLDING AG's shares went public in an IPO in the main segment of the SIX Swiss Exchange on March 31 of the same year. In 2013, the company celebrated its 100-year anniversary.
Revenues
More than 80 Percent of Net Sales with APIs
Organization & Management
DOTTIKON EXCLUSIVE SYNTHESIS AG is an entity of SIX-listed DOTTIKON ES HOLDING AG. The stable senior management and shareholder structure of the DOTTIKON ES Group enables sustainable value growth at the manufacturing site in Dottikon, Switzerland.
Board of Directors
- Dr. Markus Blocher (Chairman)
- Dr. Alfred Scheidegger (Deputy Chairman)
- Dr. Bernhard Urwyler
Senior Management
- Dr. Markus Blocher (CEO)
- Marlene Born (CFO)
- Karin Krause (Head of Human Resources)
- Dr. Stephan Kirschbaum (Head of Business Development)
- Dr. Urs Brändli (Head of Processes & Technologies)
- Dr. Thomas Rosatzin (Head of Purchasing)
- Dr. Robert Dahinden (Head of Production)
- Dr. Knut Hildebrandt (Head of Quality Management)
DOTTIKON is organized around the main processes business and process development, purchasing, production and quality management.
The production facility is located on approximately 600'000 m2 in Dottikon (Switzerland), close to Basel and Zurich. About 100'000 m2 of the premises are reserved for development of customer-driven production facilities.
Location
DOTTIKON's headquarters are located in Dottikon, Switzerland.
|
Headquarters Switzerland
Dottikon Exclusive Synthesis AG Hembrunnstrasse 17 5605 Dottikon Switzerland
|
|
Representative Office USA
Dottikon ES America, Inc.
